Vasa Denticity Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Vasa Denticity Ltd trades at ₹390, in a downtrend and 49 weeks into that stage. That is −13.4% against its own 200-day average. It sits at 15% of a 52-week range of ₹352 to ₹610. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.

Today the stock is in a downtrend — week 49 of stage 4, confirmed. At ₹390 it trades −13.4% versus its 200-day average and sits at 15% of its 52-week range (₹352–₹610).

Against the market, two honest reads. Cumulative: over the last 3.3 years the stock moved +76% while the NIFTY 500 moved +43% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Vasa Denticity Ltd trades at 58.3× P/E, near the bottom of its own range — cheaper only 28% of the time. Its long-run median P/E is 61.1×, measured across 2.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 58.3× is near the bottom of its own range — cheaper only 28% of the time, against a long-run median of 61.1× measured over 2.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved −42.2% against a −36.1% price move — the price outran earnings, pushing the multiple UP its own range.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Vasa Denticity Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −66.3% at the trough to +51.7% off a 1-quarter-old trough (single-quarter readings). The read is built from 8 quarters across 2 curves, on partial evidence.

Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

32.8/100 — rank 4 of 6 in Medical Equipment · 81% evidence confidence

Vasa Denticity Ltd scores 32.8 out of 100 against the 6 companies it is compared with in Medical Equipment, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 15.4 + 5.2 + 7.7 + 4.5 = 32.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Vasa Denticity Ltd reported ₹83.1 Cr of revenue in the Jun 26 quarter, +37.4% year on year. That is the 8th straight quarter of year-on-year growth. Over 2 years it has compounded at 28.1% a year. The last full year, FY26, came in at ₹279 Cr. The last four reported quarters add to ₹302 Cr.

FY26 revenue came in at ₹279 Cr (+15.8% on the year), capping 2 years at 28.1% compound. The latest quarter (Jun 26) printed ₹83.1 Cr, +37.4% year on year — the 8th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +18.8% growth against the decade's 28.1% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +17.9% over the last 4 quarters against +26.6%/yr over the last 8 — rolling over; TTM profit −30.2% vs −15.8%/yr — rolling over.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Vasa Denticity Ltd's operating margin is 6.1% in the Jun 26 quarter, +1.1 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 3.9% to 11.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 6.1%, +1.1 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 3.9%–11.0%.

Why the margin moved: operating margin went +1.1 pp year on year while gross margin went −8.9 pp — the gain came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Vasa Denticity Ltd earned ₹4.0 Cr of net profit in the Jun 26 quarter, +51.7% year on year. Full-year FY26 profit was ₹10.0 Cr. The 2-year compound rate is −18.4%. That is 4.9% of the quarter's revenue. The same quarter a year earlier earned ₹2.7 Cr.

Jun 26 profit was ₹4.0 Cr, +51.7% year on year. On the full year, FY26 printed ₹10.0 Cr (−41.2%), and the 2-year compound rate is −18.4%.

Why profit moved: revenue contributed +37.4% and the margin +1.1 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit −24.5% vs revenue +18.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years −95% of Vasa Denticity Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−25.0 Cr of operating cash against ₹10.0 Cr of profit. After ₹6.0 Cr of capital spending, ₹−31.0 Cr was left as free cash.

FY26: operating cash of ₹−25.0 Cr against reported profit of ₹10.0 Cr, leaving free cash of ₹−31.0 Cr after ₹6.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −95% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at −95%: the cash cycle stretched 51 days between FY24 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: conversion is below par and the cash cycle has stretched 51 days — the next section's job is to find where the cash is stuck.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Vasa Denticity Ltd's cash conversion cycle runs 141 days in FY26, up from 90 days in FY24. Capital spending ran ₹27.0 Cr over the last 2 years. At FY26 sales of ₹279 Cr each day of that cycle holds about ₹0.8 Cr, so roughly ₹108 Cr sits inside the business at any moment.

FY26: debtors at 16 days, inventory at 151 days — roughly 5.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 141 days, looser than FY24's 90.

The full loop: cash goes out to suppliers and production on day 0; stock waits 151 days to sell; customers pay about 16 days after that; and suppliers themselves are paid at 26 days — netting out to the 141-day cycle.

In money terms: at FY26 sales of ₹279 Cr, each day of the cycle holds about ₹0.8 Cr — so the 141-day loop keeps roughly ₹108 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹27.0 Cr over the last 2 fiscal years against ₹4.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹1.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Vasa Denticity Ltd earns a ROCE of 9% in FY26. Return on invested capital clears the cost of that capital by −6.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 3.6% net margin on 1.42× asset turns.

FY26 ROCE is 9%.

🚨 Why the return is what it is — the wiring (FY26): 3.6% net margin × 1.42× asset turns × 1.13× balance-sheet leverage ≈ 5.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 5.4% − 12.0% = a −6.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Vasa Denticity Ltd carries total debt of ₹0.0 Cr against shareholder equity of ₹175 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.06 in FY23 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹0.0 Cr against shareholder equity of ₹175 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.06 (FY23) to 0.00 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters cut 9.4 points of Vasa Denticity Ltd over 8 quarters, the biggest move on the register. That takes promoters to 60.2% of the company. Foreign institutions moved +6.9 points over the same window, to 6.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: −9.4 points over 8 quarters to 60.2%; Foreign institutions: +6.9 points over 8 quarters to 6.9%; Domestic institutions: +1.5 points over 8 quarters to 2.2%.

🚨 Why the register moved: promoters drove it (−9.4 points), absorbed on the other side by foreign institutions (+6.9 points) — distribution into the market’s bid.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Vasa Denticity Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions